• Je něco špatně v tomto záznamu ?

Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis

T. Smutny, I. Barvik, T. Veleta, P. Pavek, T. Soukup,

. 2019 ; 8 (5) : . [pub] 20190427

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19029062

Grantová podpora
00179906 MH CZ - DRO UHHK
PROGRES Q40-15, PROGRES Q47 Charles University research projects
[No. CZ.02.1.01/0.0/0.0/16_019/0000841] co-funded by ERDF EFSA-CDN

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related chronic inflammatory diseases. Glucocorticoids (GCs) are first-choice drugs for PMR and GCA, although some patients show poor responsiveness to the initial GC regimen or experience flares after GC tapering. To date, no valid biomarkers have been found to predict which patients are at most risk for developing GC resistance. In this review, we summarize PMR- and GCA-related gene polymorphisms and we associate these gene variants with GC resistance and therapeutic outcomes. A limited number of GC resistance associated-polymorphisms have been published so far, mostly related to HLA-DRB1*04 allele. Other genes such ICAM-1, TLR4 and 9, VEGF, and INFG may play a role, although discrepancies are often found among different populations. We conclude that more studies are required to identify reliable biomarkers of GC resistance. Such biomarkers could help distinguish non-responders from responders to GC treatment, with concomitant consequences for therapeutic strategy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19029062
003      
CZ-PrNML
005      
20190823101607.0
007      
ta
008      
190813s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jcm8050582 $2 doi
035    __
$a (PubMed)31035618
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Smutny, Tomas $u Department of Pharmacology and Toxicology, Centre for Drug Development, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. smutt6aa@faf.cuni.cz.
245    10
$a Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis / $c T. Smutny, I. Barvik, T. Veleta, P. Pavek, T. Soukup,
520    9_
$a Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related chronic inflammatory diseases. Glucocorticoids (GCs) are first-choice drugs for PMR and GCA, although some patients show poor responsiveness to the initial GC regimen or experience flares after GC tapering. To date, no valid biomarkers have been found to predict which patients are at most risk for developing GC resistance. In this review, we summarize PMR- and GCA-related gene polymorphisms and we associate these gene variants with GC resistance and therapeutic outcomes. A limited number of GC resistance associated-polymorphisms have been published so far, mostly related to HLA-DRB1*04 allele. Other genes such ICAM-1, TLR4 and 9, VEGF, and INFG may play a role, although discrepancies are often found among different populations. We conclude that more studies are required to identify reliable biomarkers of GC resistance. Such biomarkers could help distinguish non-responders from responders to GC treatment, with concomitant consequences for therapeutic strategy.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Barvik, Ivan $u Institute of Physics, Faculty of Mathematics and Physics, Charles University, 121 16 Prague, Czech Republic. ibarvik@karlov.mff.cuni.cz.
700    1_
$a Veleta, Tomas $u Department of Emergency Medicine, University Hospital in Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. tomas.veleta@fnhk.cz.
700    1_
$a Pavek, Petr $u Department of Pharmacology and Toxicology, Centre for Drug Development, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. pavek@faf.cuni.cz.
700    1_
$a Soukup, Tomas $u Division of Rheumatology, 2nd Department of Internal Medicine⁻Gastroenterology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital in Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. soukutom@fnhk.cz.
773    0_
$w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 8, č. 5 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31035618 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190823101822 $b ABA008
999    __
$a ind $b bmc $g 1434211 $s 1067522
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 8 $c 5 $e 20190427 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
GRA    __
$a 00179906 $p MH CZ - DRO UHHK
GRA    __
$a PROGRES Q40-15, PROGRES Q47 $p Charles University research projects
GRA    __
$a [No. CZ.02.1.01/0.0/0.0/16_019/0000841] co-funded by ERDF $p EFSA-CDN
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace